论文信息 - Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.

Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.

3009Background: Autologous T cells genetically modified to express a CD19-targeting CAR (CTL019) can mediate potent anti-tumor effects in CLL and other CD19+ malignancies. Since CTL019 are self-rep...